J
J. M. Ladero
Researcher at Complutense University of Madrid
Publications - 17
Citations - 377
J. M. Ladero is an academic researcher from Complutense University of Madrid. The author has contributed to research in topics: Genotype & Debrisoquine. The author has an hindex of 10, co-authored 17 publications receiving 373 citations. Previous affiliations of J. M. Ladero include University of Extremadura.
Papers
More filters
Journal ArticleDOI
Increased risk for hepatocellular carcinoma in NAT2-slow acetylators and CYP2D6-rapid metabolizers
José A. G. Agúndez,Manuela Olivera,J. M. Ladero,Álvaro Rodríguez-Lescure,María C. Ledesma,Manuel Díaz-Rubio,Urs A. Meyer,Julio Benítez +7 more
TL;DR: The genetic polymorphism of NAT2 is a relevant factor in the risk for developing HCC (inverse odds ratio slow vs rapid = 1.8; 95% CI 1.1-3.0) and the additional determination of alleles of the cytochrome P450 2D6 (CYP2D6) gene in the same subjects confirmed the previous findings that subjects with two active CYP2D 6 genes are at increased risk of developing H CC.
Journal ArticleDOI
Expression in human prostate of drug- and carcinogen-metabolizing enzymes: association with prostate cancer risk.
José A. G. Agúndez,Cristina del Barrio Martínez,Manuela Olivera,Lourdes Gallardo,J. M. Ladero,C. Rosado,Jose Prados,J. Rodriguez-Molina,L. Resel,Julio Benítez +9 more
TL;DR: The presence of carcinogen-metabolizing enzymes in human prostate with a high interindividual variability may be involved in the regulation of local levels of carcinogens and mutagens and may underlie interindividual differences in cancer susceptibility.
Journal ArticleDOI
Slow allotypic variants of the NAT2 gene and susceptibility to early-onset Parkinson's disease
José A. G. Agúndez,F J Jiménez-Jiménez,Antonio Luengo,JoséAntonio Molina,M. Ortí-Pareja,Antonio A. Vázquez,F. Ramos,Jacinto Duarte,F. Coria,J. M. Ladero,José C. Álvarez-Cermeño,Julio Benítez +11 more
TL;DR: Slow-acetylation-mutated alleles may be considered low-penetrance genes in early-onset PD pathogenesis, with a relative risk ratio for individuals with slow- acetylation genotype of 2.92 (95% CI, 1.26 to 6.78).
Journal ArticleDOI
Oxidative polymorphism of debrisoquine in Parkinson's disease.
Julio Benítez,J. M. Ladero,F J Jiménez-Jiménez,Carmen Martínez,A. M. Puerto,Maria J. Valdivielso,Adrián LLerena,J. Cobaleda,Juan J. Muñoz +8 more
TL;DR: A negative correlation was found between MR of DBQ and age at onset of disease in patients free of drugs known to interact with DBQ metabolism, which could be a genetic factor that delays the clinical onset of Parkinson's disease in predisposed people.